High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT

R. Tizon, N. Frey, D. F. Heitjan, K. S. Tan, S. C. Goldstein, E. O. Hexner, A. Loren, S. M. Luger, R. Reshef, D. Tsai, D. Vogl, J. Davis, M. Vozniak, B. Fuchs, E. A. Stadtmauer, D. L. Porter

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Idiopathic Pneumonia Syndrome (IPS) is a common complication after allo-SCT and results in high mortality rates. Conventional treatment for IPS typically includes supportive care and high-dose corticosteroids (CS). Data suggests that TNF-α is important in the pathogenesis of IPS and that the TNF-α inhibitor etanercept may be useful for IPS treatment. We performed a retrospective comparison of consecutive patients treated at our center for IPS with CS only from 1999 to 2003 (group 1, n=22) or CS plus etanercept from 2004 to 2007 (group 2, n=17). In all, 18% of patients in group 1 vs 53% in group 2 were successfully taken off respiratory support and discharged from the hospital (P=0.039). OS was significantly better for recipients of CS plus etanercept (P=0.003). The estimated survival at 28 days and 2 years after IPS was 36.4% (95% CI 17-56%) and 9.1% (95% CI 2-25%) for group 1 and 88.2% (95% CI 61-97%) and 18% (95% CI 4-38%) for group 2, respectively. Our retrospective comparison suggests that the addition of etanercept to CS for IPS improves response rates and OS. However, outcomes remain limited in both groups, highlighting the need for more effective interventions to treat early and late complications of IPS.

Original languageEnglish (US)
Pages (from-to)1332-1337
Number of pages6
JournalBone Marrow Transplantation
Volume47
Issue number10
DOIs
StatePublished - Oct 1 2012

Fingerprint

Pneumonia
Adrenal Cortex Hormones
Therapeutics
Etanercept
Survival
Mortality

Keywords

  • Allo-SCT
  • Etanercept
  • Idiopathic Pneumonia Syndrome
  • TNF-α

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. / Tizon, R.; Frey, N.; Heitjan, D. F.; Tan, K. S.; Goldstein, S. C.; Hexner, E. O.; Loren, A.; Luger, S. M.; Reshef, R.; Tsai, D.; Vogl, D.; Davis, J.; Vozniak, M.; Fuchs, B.; Stadtmauer, E. A.; Porter, D. L.

In: Bone Marrow Transplantation, Vol. 47, No. 10, 01.10.2012, p. 1332-1337.

Research output: Contribution to journalArticle

Tizon, R, Frey, N, Heitjan, DF, Tan, KS, Goldstein, SC, Hexner, EO, Loren, A, Luger, SM, Reshef, R, Tsai, D, Vogl, D, Davis, J, Vozniak, M, Fuchs, B, Stadtmauer, EA & Porter, DL 2012, 'High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT', Bone Marrow Transplantation, vol. 47, no. 10, pp. 1332-1337. https://doi.org/10.1038/bmt.2011.260
Tizon, R. ; Frey, N. ; Heitjan, D. F. ; Tan, K. S. ; Goldstein, S. C. ; Hexner, E. O. ; Loren, A. ; Luger, S. M. ; Reshef, R. ; Tsai, D. ; Vogl, D. ; Davis, J. ; Vozniak, M. ; Fuchs, B. ; Stadtmauer, E. A. ; Porter, D. L. / High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 10. pp. 1332-1337.
@article{286a518f0f9347e19428bafd4198c22c,
title = "High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT",
abstract = "Idiopathic Pneumonia Syndrome (IPS) is a common complication after allo-SCT and results in high mortality rates. Conventional treatment for IPS typically includes supportive care and high-dose corticosteroids (CS). Data suggests that TNF-α is important in the pathogenesis of IPS and that the TNF-α inhibitor etanercept may be useful for IPS treatment. We performed a retrospective comparison of consecutive patients treated at our center for IPS with CS only from 1999 to 2003 (group 1, n=22) or CS plus etanercept from 2004 to 2007 (group 2, n=17). In all, 18{\%} of patients in group 1 vs 53{\%} in group 2 were successfully taken off respiratory support and discharged from the hospital (P=0.039). OS was significantly better for recipients of CS plus etanercept (P=0.003). The estimated survival at 28 days and 2 years after IPS was 36.4{\%} (95{\%} CI 17-56{\%}) and 9.1{\%} (95{\%} CI 2-25{\%}) for group 1 and 88.2{\%} (95{\%} CI 61-97{\%}) and 18{\%} (95{\%} CI 4-38{\%}) for group 2, respectively. Our retrospective comparison suggests that the addition of etanercept to CS for IPS improves response rates and OS. However, outcomes remain limited in both groups, highlighting the need for more effective interventions to treat early and late complications of IPS.",
keywords = "Allo-SCT, Etanercept, Idiopathic Pneumonia Syndrome, TNF-α",
author = "R. Tizon and N. Frey and Heitjan, {D. F.} and Tan, {K. S.} and Goldstein, {S. C.} and Hexner, {E. O.} and A. Loren and Luger, {S. M.} and R. Reshef and D. Tsai and D. Vogl and J. Davis and M. Vozniak and B. Fuchs and Stadtmauer, {E. A.} and Porter, {D. L.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1038/bmt.2011.260",
language = "English (US)",
volume = "47",
pages = "1332--1337",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT

AU - Tizon, R.

AU - Frey, N.

AU - Heitjan, D. F.

AU - Tan, K. S.

AU - Goldstein, S. C.

AU - Hexner, E. O.

AU - Loren, A.

AU - Luger, S. M.

AU - Reshef, R.

AU - Tsai, D.

AU - Vogl, D.

AU - Davis, J.

AU - Vozniak, M.

AU - Fuchs, B.

AU - Stadtmauer, E. A.

AU - Porter, D. L.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Idiopathic Pneumonia Syndrome (IPS) is a common complication after allo-SCT and results in high mortality rates. Conventional treatment for IPS typically includes supportive care and high-dose corticosteroids (CS). Data suggests that TNF-α is important in the pathogenesis of IPS and that the TNF-α inhibitor etanercept may be useful for IPS treatment. We performed a retrospective comparison of consecutive patients treated at our center for IPS with CS only from 1999 to 2003 (group 1, n=22) or CS plus etanercept from 2004 to 2007 (group 2, n=17). In all, 18% of patients in group 1 vs 53% in group 2 were successfully taken off respiratory support and discharged from the hospital (P=0.039). OS was significantly better for recipients of CS plus etanercept (P=0.003). The estimated survival at 28 days and 2 years after IPS was 36.4% (95% CI 17-56%) and 9.1% (95% CI 2-25%) for group 1 and 88.2% (95% CI 61-97%) and 18% (95% CI 4-38%) for group 2, respectively. Our retrospective comparison suggests that the addition of etanercept to CS for IPS improves response rates and OS. However, outcomes remain limited in both groups, highlighting the need for more effective interventions to treat early and late complications of IPS.

AB - Idiopathic Pneumonia Syndrome (IPS) is a common complication after allo-SCT and results in high mortality rates. Conventional treatment for IPS typically includes supportive care and high-dose corticosteroids (CS). Data suggests that TNF-α is important in the pathogenesis of IPS and that the TNF-α inhibitor etanercept may be useful for IPS treatment. We performed a retrospective comparison of consecutive patients treated at our center for IPS with CS only from 1999 to 2003 (group 1, n=22) or CS plus etanercept from 2004 to 2007 (group 2, n=17). In all, 18% of patients in group 1 vs 53% in group 2 were successfully taken off respiratory support and discharged from the hospital (P=0.039). OS was significantly better for recipients of CS plus etanercept (P=0.003). The estimated survival at 28 days and 2 years after IPS was 36.4% (95% CI 17-56%) and 9.1% (95% CI 2-25%) for group 1 and 88.2% (95% CI 61-97%) and 18% (95% CI 4-38%) for group 2, respectively. Our retrospective comparison suggests that the addition of etanercept to CS for IPS improves response rates and OS. However, outcomes remain limited in both groups, highlighting the need for more effective interventions to treat early and late complications of IPS.

KW - Allo-SCT

KW - Etanercept

KW - Idiopathic Pneumonia Syndrome

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=84867395638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867395638&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.260

DO - 10.1038/bmt.2011.260

M3 - Article

C2 - 22307018

AN - SCOPUS:84867395638

VL - 47

SP - 1332

EP - 1337

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -